In vitro inhibition of human malignant brain tumour cell line proliferation by anti urokinase-type plasminogen activator monoclonal antibodies

British Journal of Cancer

Volumn 78, Issue 12, 1998, Pages 1578-1585

  Abaza, M S I ^a   Shaban, F A ^a   Narayan, R K ^a   Zouhair Atassi, M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Anti proliferative activity; Anti UK MAb; Cell line; Expression; Glioma; Surface location

Indexed keywords

ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; CELL SURFACE PROTEIN; MONOCLONAL ANTIBODY; UROKINASE;

ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; BRAIN TUMOR; CANCER INHIBITION; CELL SURVIVAL; CONTROLLED STUDY; CROSS REACTION; CYTOLYSIS; DNA SYNTHESIS; ELECTROPHORESIS; ENZYME LOCALIZATION; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOBLOTTING; METASTASIS; MOLECULAR WEIGHT; PRIORITY JOURNAL; RADIOIMMUNOASSAY;

EID: 0031768480     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.726     Document Type: Article

References (50)

1. Abaza MSI and Atassi MZ (1992) Effects of amino acid substitutions outside an antigenic site on protein binding to monoclonal antibodies of predetermined specificity obtained by peptide immunization: demonstration with region 94-100 (antigenic site 3) of myoglobin. J Prot Chem 11: 433
2. Achbarou A, Kaiser S, Tremblay G, Ste-Marie LG, Brodt P, Goltzman D and Rabbani SA (1994) Urokinase over-production results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res 54: 2372-2377
3. Bianchi E, Cohen RL, Thor AT and Todd RF, Lawrence DA, Ljung BM, Shuman MA and Smith HS (1994) The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue. Cancer Res 54(4): 861-866
4. Booth NA, Bennett B, Wijngaards G and Grieve JHK (1983) A new life long hemorrhage disorder due to excess plasminogen activator. Blood 61: 207
5. Bouchet C, Spyratos F, Martin PM, Hacene K, Gentile A, and Oglobine J (1994) The prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas. Br J Cancer 69(2): 398-405
6. Burnette WN (1981) Electrophoretic transfers of proteins from sodium dodecyl sulfate polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A. Anal Biochem 112: 195
7. Dano K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS and Skriver L (1986) Plasminogen activators, tissue degradation, and Cancer. Adv Cancer Res 44: 139-266
8. Duffy MJ (1987) Do proteases play a role in cancer invasion and metastasis? Eur J Cancer Clin Oncol 23: 583-589
9. Foekens JA, Schmitt M, Van Pulten WL, Peters HA, Bontenbal M, Janicke F and Klijn JG (1992) Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 52(21): 6101-6105
10. Gerdin B and Saldeen T (1978) Effect of fibrin degradation products on microvascular permeability. Thromb Res 13: 995
11. Grimann G, Press H, Schwartze G and Scheurlen PG (1976) Immunosuppression by micromolecular fibrinolysis degradation products in cancer. Nature 259: 399
12. G-Nzler WA, Steffens GJ, Otting F, Buse G and Flohe L (1982a) Structural relationship between human high and low molecular mass urokinase. Hoppe-Seyler's Z Physiol Chem 363: 133
13. G-Nzler WA, Steffens GJ, Otting F, Kim SM, Frankus E and Floche L (1982b) The primary structure of high molecular mass urokinase from human urine. The complete amino acid sequence of the A-chain. Hoppe-Seyler's Z Physiol Chem 363: 1155
14. Hollas W, Hoosein N, Chung LW, Mazar A, Henkin J, Kariko K, Barnathan ES and Boyd D (1992) Expression of urokinase and its receptor in invasive and non-invasive prostate cancer cell lines. Thrombosis Haemostasis 68(6): 662-666
15. Hoosein NM, Boyd D, Hollas WJ, Mazar A, Henkin J and Chung LW (1991) Involvement of urokinase and its receptor in the invasiveness of human prostatic carcinoma cell lines. Cancer Commun 3(8): 255-264
16. Hsui Y, Nishi S, Kitado S and Osada Y (1993) Urokinase-type plasminogen activator antigen as a prognostic factor in bladder cancer. Nippon Hinyokiko Gakkai Zasshi-Japanese J Urol 84(9): 1624-1628
17. Janicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Hofler H and Graeff H (1993) Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 24: 195-208
18. Kalderon N (1984) Schwann cell proliferation and localized proteolysis: expression of plasminogen-activator predominates in the proliferating cell populations. Proc Natl Acad Sci USA 81: 7216
19. Kobayashi H, Obi H, Sugimura M, Shinohara H, Fujii T and Teras T (1992) Inhibition of in vitro ovaarian cancer cell invasion by modulation of urokinase-type plasminogen activator and cathepsin B. Cancer Res 52: 3610-3614
20. Kobayashi H, Moniwa N, Sugimura M, Shinohara H, Ohi H and Terao T (1993) Increased cell-surface urokinase in advanced ovarian cancer. Jpn J Cancer Res 84(6):633-640
21. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680
22. Miskin R and Reich E: (1980) Plasminogen activator: induction of synthesis by DNA damage. Cell 19: 217
23. Moser TL, Young TN, Rodriguez GC, Pizzo SV, Bast RC Jr and Stack MS (1994) Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinoma. Int J Cancer 56(4): 552-559
24. Ng R and Kellen JA (1983) The role of plasminogen activators in metastasis. Med Hypothesis 10: 291
25. Nielsen LS, Hansen JG, Skriver L, Wilson EL, Kaltoft K. Zeuthen J and Dan K (1982) Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody. Biochemistry 21: 6410
26. Ossowski L, Unkeless JC, Tobia A, Quigley JP, Rifkin DB and Reich E (1973) An enzymatic function associated with transformation of fibroblasts by oncogenic viruses (II). J Exp Med 137: 497
27. Plow EF, Freaney D and Edgnigton TS (1982) Inhibition of lymphocyte protein synthesis by fibrinogen-derived peptides. J Immunol 128: 1595
28. Pujade-Lauraine E, Lu H, Mirshahi S, Soria J, Soria C, Bernadou A, Kruithof EK, Lijnen HR and Burtin P (1993) The plasminogen-activation system in ovarian tumors. Int J Cancer 55(1): 27-31
29. Raymond NG and Kellen JA (1983) The role of plasminogen activators in metastasis. Med Hypoth 10: 291
30. Reich E (1978) Activation of plasminogen: a general mechanism for producing localized extracellular proteolysis. In Molecular Basis of Biological Degradative Process, Berlin RD, Herrmann H, Lepow IH and Tanzer JM (eds), pp. 155-169. Academic Press: New York
31. Reich E (1978) Activation of plasminogen. A widespread mechanism for generating localized extracellular proteolysis. In Biological Markers of Neoplasia: Basic and Applied Aspects, Rudden EW (ed), pp. 491-500. Elsevier: New York
32. Reith A and Rucklidge GJ (1992) Invasion of brain tissue by primary glioma: evidence for the involvement of urokinase-type plasminogen activator as an activator of type IV collagenase. Biochem Biophys Res Commun 186(1): 348-354
33. Riccio A, Grimaldi G, Verde P, Sebastio G, Boast S and Blasi F (1985) The human urokinase-plasminogen activator gene and its promotor. Nucleic Acids Res 13: 2759
34. Salerno G, Verde P, Nolli ML, Corti A, Szots H, Meo T, Johnson J, Bullock S, Cassani G and Blasi F (1984) Monoclonal antibodies to human urokinase identify the single-chain pro-urokinase precursor. Proc Natl Acad Sci USA 81: 110
35. Salo T, Liotta LA, Keshi-Oju J. Turpeenniemi-Hujanen T and Tryggvasson K (1982) Secretion of basement membrane collagen degrading enzyme and plasminogen activator by transformed cells, role in metastasis. Int J Cancer 30: 669
36. Sobel GW, Mohler SR, Jones NW, Dowdy ABC and Guest MM (1952) Urokinase: an activator of plasma fibrinolysis extracted from urine. Am J Physiol 171: 768
37. Strickland S (1980) Development in Mammals. Vol. 4. Johnson MH (ed.) pp. 81-100. Elsevier: New York
38. Sumiyoshi K, Serizawa K, Urano T, Takada Y and Baba S (1492) Plasminogen activator system in human breast cancer. Int J Cancer 50(3): 345-348
39. Towbin H, Staehelin T and Gordon J (1979) Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets; procedure and some applications. Proc Natl Acad Sci USA 76: 4350
40. +) RNA. Proc Natl Acad Sci 81: 4727
41. Wainberg MA, Israel E and Margolese RG (1982) Further studies on the mitogenic and immune-modulating effects of plasminogen activator. Immunology 45: 715
42. Webber MM, James G, Lucero L, Van Buskirk JJ and Wettlaufer JN (1981) Plasminogen activator: a marker for human prostatic epithelium and prostate cancer. In Vitro 17: 249
43. Wigler M and Weinstein IB (1976) Tumor promoter induces plasminogen activator. Nature 259: 232
44. Wilson EL, Becker MLB. Hoal EG and Dowdle EB (1980) Molecular species of plasminogen activators secreted by normal and neoplastic human cells. Cancer Res 40: 433
45. Wilson EL and Dowdle E (1974) Secretion of plasminogen activator by normal. reactive and neoplastic human tissues cultured in vitro. Int J Cancer 22: 390
46. Wilson EL and Reich E (1978) Plasminogen activator in chicken fibroblasts: induction of synthesis by retinoic acid; synergisin with viral transformation and phorbol ester. Cell 15: 385
47. Wun T, Ossowski L and Reich L (1982) A proenzyme form of human urokinase. J Biol Chem 257: 7262
48. Yamashita J, Ogawa M, Inada K, Yamashita S, Nakashima Y, Saishoji T and Nomura K (1993) Breast cancer prognosis is poor when total plasminogen activator activity is low. Br J Cancer 67(2): 374-378
49. Young TN, Rodriguez GC, Moser T, Bast Jr, R, Pizzo SV and Stack MS (1994) Coordinate expression of urinary type plasminogen activator and its receptor accompanies malignant transformation of the ovarian surface epithelium. Am J Obstetrics Gynecol 170(5pt 1): 1285-1296
50. Xucker SA (1988) Critical appraisal of the role of proteolytic enzymes in cancer invasion: emphasis on tumor surface proteinases. Cancer Invest 6: 219-231